Thursday, April 16, 2026 – A recent poll found 1 in 8 adults take a GLP-1 medication like Ozempic or Wegovy and 27 percent of those users said even though they have insurance, they still pay out-of-pocket for those drugs. NBC News medical contributor Dr. Natalie Azar and chief business correspondent Christine Romans join TODAY to break down the different weight loss drugs, how to know if your insurance will cover them and more.
Wednesday, April 15, 2026 – Thursday, April 16 - Insurance coverage of blockbuster obesity drugs has been spotty at best over the years, and it looks like things are getting worse, not better. Plans are dropping coverage or restricting it further.
Wednesday, April 15, 2026 – Wednesday, April 16 - If you watched the Super Bowl in 2026, you likely saw Serena Williams share her weight loss journey on GLP-1 medications in a commercial.
Wednesday, April 15, 2026 – Wednesday, April 16 - Over the past few years, GLP-1 receptor agonists have been growing in popularity for weight loss.
While many people lose between 5-15% of their starting body weight while on a GLP-1, as much as 20% of people may not respond to the drug.
Recent research has found that a person’s genetic makeup may explain why some people do not respond to GLP-1 drugs.
A new review suggests that taking both a GLP-1 medication, and a medication that combines both naltrexone and bupropion into one pill, may be helpful for those who are not responding to GLP-1s alone.
Wednesday, April 15, 2026 – Wednesday, April 15 - A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs.
Tuesday, April 14, 2026 – Wednesday, April 15 - (MedPage Today) -- Eating the same meals every day may aid in weight loss, according to a study of real-time food tracking data. (Health Psychology)
The prevalence of youth-onset type 2 diabetes increased substantially from 2013 to 2024, rising...
Tuesday, April 14, 2026 – Wednesday, April 15 - Research has found that the effectiveness of GLP-1 drugs may vary based on a person’s genetics. Image Credit: Indranil MUKHERJEE / AFP via Getty Images
GLP-1 medications may not always be effective for everyone.
New research suggests that around 10% of people carry genetic variations that explain why.
Tuesday, April 14, 2026 – Wednesday, April 15 - Researchers at Toronto's Sinai Health have found that semaglutide—the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1—acts directly on a subset of liver cells to improve organ function and does so independently of weight loss. The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic liver disease.
Tuesday, April 14, 2026 – Wednesday, April 15 - With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.
Tuesday, April 14, 2026 – Tuesday, April 14 - Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesityFaced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years. Continue reading...